Accelerate drug development and commercialization using big data.

Phesi harnesses the power of real-time dynamic data to maximize successful outcomes in drug development. Our integrated and systematic approach, combined with our AI-powered platform, is revolutionizing the clinical trials industry.

Read more
Phesi advantage

Why Phesi?

Phesi is a leading provider of integrated, automated and comprehensive virtual clinical development solutions to more than 30 of the top 50 worldwide pharmaceutical companies. For almost two decades, we’ve helped our clients improve productivity, reduce costs, and save time in all aspects of clinical study workflow.

Our focus on flexible and customized services coupled with our deep domain knowledge makes us the choice of over 80 leading pharma companies. Our clients choose Phesi for protocol design, including the use of synthetic data and control arms, trial forecasting, optimization, rescue and to reduce patient burden.

Read more

Unprecedented volume of data on global clinical research data.

Transform unstructured information into new clinical research data with artificial intelligence.

Predictive modeling capable of accurate what-if analysis.

Defines and applies advanced data science for clinical development.

485 k

Curated clinical trials

4.2 m


80 k

Updated data sources

30 m+

Patient records

4000 +

Disease indications


Protocol Design and Optimization

Phesi provides advanced analytics and a systematic, holistic data science approach to transform how you plan the design, development and optimization of clinical trials. Our approach enables you to uncover new insights from data to accelerate your drug development projects, overcome recruitment challenges, and create user-centric trials that deliver results. Phesi ensures you can stop hoping your clinical trials will work out, and start knowing.

Read more

Strategic Development

Read more

Synthetic Control

Read more

Ongoing Trial

Read more
our clients

Customer experience

Phesi is on the frontiers of defining clinical development as a science, performing systematic analysis of the clinical trial, clinical protocol, and clinical site space to form hypotheses about what will work and what will not. Through observation and experiment you are applying those learnings to inform new clinical programs or save old ones. Phesi is more than the sum of its parts and the value is in the integration.


Every global R&D leader should know about this and should be testing it within their portfolio.

senior director, clinical operations Takeda

Phesi worked with us to show that a particular adaptive trial design would give the best performance. The result was a significantly quicker and cheaper devel­opment time on this priority asset.

senior director, clinical operations Takeda
News & events
09. 21. 2022
New Phesi Analysis of 117,000 Alzheimer’s Patients Highlights Need for Preventative Approach that Includes Younger Participants Read more
06. 23. 2022
48% of US cancer clinical trials have no Hispanic or Latin American representation, and 42% do not include a single Black patient, Phesi analysis reveals Read more
06. 01. 2022
Use of digital twins will be essential in accelerating the use of CAR-T in cancer treatment and mitigating the side effects, says Phesi Read more
05. 06. 2022
Phesi global analysis of 2.5 million patients finds participants in breast cancer clinical trials are getting younger Read more
03. 21. 2022
New Phesi data highlights potential long-lasting impact from war in Ukraine on global clinical development Read more
02. 03. 2022
Only 14% of breast cancer trials reached optimal enrolment targets in 2021, despite being the most studied indication globally Read more